Xspray's Q3 release was undramatic with the primary near-term happenings relating to the ongoing FDA inspection at NerPharMa and the newly announced rights issue of up to SEK162m. The raise secures funding through the expected 2027 approvals of Dasynoc and Nilopki, and the inspection outcome should be available within the coming few weeks and will determine the path for the case. The stock screens as 'Attractively priced' compared to Redeye's fair value of SEK37.
LÄS MER
